We report on a term newborn with an unusual presentation and course of a rare lung disease due to mutation in SFTPC gene. This particular SFTPC mutation is novel, and the infant's lung disease was unusually severe compared to what has been previously reported in association with SFTPC mutations.
Introduction
Pulmonary surfactant is a complex mixture of phospholipids and proteins that is synthesized by type II alveolar pneumocytes. Surfactant lowers surface tension at the air-liquid interface, thereby maintaining alveolar expansion at end expiration. Of the four surfactant associated proteins (surfactant protein (SP)-A, SP-B, SP-C and SP-D), SP-B and SP-C interact with phospholipid components in a tightly coordinated itinerary of synthesis, secretion, film formation and recycling. 1 Pulmonary SP-C is a highly hydrophobic peptide produced by type II alveolar cells through the processing of a high molecular weight precursor (proSP-C) that enhances surface tension and facilitates the recycling of pulmonary surfactant in vitro. SFTPC gene is short, spanning only 3500 base pairs on the short arm of chromosome 8 (8p23.1) near the gene coding for bone morphogenetic protein 1. SP-C deficiency and mutations in the SFTPC have been associated with interstitial lung disease (ILD) in children and adults. [2] [3] [4] [5] Hereditary SP-B deficiency, with over 20 different mutations of SP-B, is a well established cause of severe respiratory failure in newborns. 6 Mutation in SFTPC with resultant SP-C deficiency that presents as respiratory failure in the neonatal period is a rare entity. We report on a neonate who presented with progressive respiratory failure and was diagnosed to have mutation in SFTPC gene.
Case report
A full term (39 weeks), male infant weighing 2940 g was born to a 36-year-old healthy gravida 3 para 1 mother by cesarean section after failed vacuum extraction. Apgar scores were 9 and 9 at 1 and 5 min, respectively.
The infant was well until day 3 of life. At that time, physical examination revealed tachypnea and chest retractions; hence, the infant was transferred to the special care nursery. A complete sepsis work up was done and antibiotics were commenced. The infant was started on 30% inspired oxygen via nasal prongs. A capillary blood gas revealed pH ¼ 7.32, PCO 2 ¼ 53, PO 2 ¼ 45; HCO 3 ¼ 27 and BE ¼ 1. The chest radiograph revealed mildly hyperinflated lungs and mild perihilar interstitial markings (Figure 1 ). Echocardiogram showed an anatomically normal heart with no structural malformation. On day 7, the infant developed progressive increase in work of breathing with increasing oxygen requirement; continuous positive airway pressure was initiated. Chest radiograph showed increasing haziness of both lung fields with air bronchograms (Figure 2 ). On day 10, the infant developed progressive respiratory acidosis followed by intubation, mechanical ventilation and transport to a neonatal intensive care unit (NICU).
In the NICU, examination revealed the following: temperature 37.41C pulse rate 160/min, respiratory rate 90/min and blood pressure 72/42 mmHg. Systemic examination was unremarkable except for respiratory distress. There was no clinical evidence of pulmonary hypertension. He was initially ventilated on pressure settings of 20/4 cm H 2 O with a ventilatory rate of 60/min and 80% inspired oxygen. An arterial blood gas revealed hypoxia and respiratory acidosis (pH ¼ 7.35; PaCO 2 ¼ 60; PaO 2 ¼ 41 and HCO 3 ¼ 32 with a/A ratio of 0.13 and oxygenation index (OI) of 14).
A complete sepsis work up was repeated. The white blood cell count was unremarkable. Chest radiograph revealed diffuse ground glass appearance with air bronchogram (Figure 3 ). Nasopharyngeal and tracheal aspirates were sent for viral (antigen testing for Influenza A and B, Para influenza A and B, Respiratory syncytial virus, Herpes simplex and Adenovirus), chlamydia and mycoplasma cultures that were subsequently reported as negative.
He was treated with antibiotics; acyclovir and bovine lipid extract surfactant. After the surfactant administration, the inspired oxygen was reduced to 60% with improvement in the blood gas (pH ¼ 7.39; PaCO 2 ¼ 52; PaO 2 ¼ 99; HCO 3 ¼ 31 and a/A ¼ 0.37 with OI ¼ 5). Tracheal aspirate sample for surfactant protein analysis was collected 24 h after the first dose of surfactant. Based on the clinical response to surfactant and radiographic findings, he was suspected to have surfactant protein deficiency. After informed and written parental consent, tracheal aspirate and blood for molecular typing for surfactant protein were sent to DNA Diagnostic laboratory (CLIA certified) at Johns Hopkins Hospital (http:// www.hopkinsmedicine.org/dnadiagnostic).
Assisted ventilatory support was continued. He required high ventilatory pressures and FiO 2 . He was treated with repeated doses of surfactant every 24-26 h. Dexamethasone treatment was intermittently attempted with apparent pulmonary improvement as assessed by ability to reduce the frequency of surfactant administration. Computerized tomography (CT) studies of the chest showed diffuse atelectasis, bronchial inflation and accentuation of interlobular septa. There were no focal parenchymal or mass lesions.
On day 25 of life, he developed temperature instability, feeding intolerance, tachycardia and increasing oxygen requirement. Laboratory studies showed leukocytosis with a left shift; C-reactive protein of 28 mg/l (normal: 0-8 mg/l) and bacteremia with coagulase negative staphylococcus. He was treated with vancomycin for 7 days. During this episode, he required more frequent surfactant therapy every 18-24 h. He also developed hepatosplenomegaly and conjugated hyperbilirubinemia. Abdominal ultrasonography showed hepatosplenomegaly, but no structural or focal lesions on abdominal ultrasonography.
Initial results of the surfactant protein studies showed the presence of surfactant protein B in the tracheal aspirate. However, his clinical course, response to surfactant and radiological findings indicated functional surfactant protein deficiency. Subsequently, DNA sequencing showed a single base deletion (Nt 392 del T) in exon 4 of SFTPC gene.
On day of life 44, he developed unremitting hypoxemia that was unresponsive to surfactant therapy. The ventilator management was withdrawn with death ensuing thereafter. All family members of this infant including the siblings are healthy without respiratory symptoms.
Discussion
In this report, we describe a term infant with progressive fatal respiratory failure during the first 2 months of life that was associated with mutation (Nt 392 del T) in exon 4 of SFTPC gene. This deletion causes a shift in the open reading frame resulting in a premature stop codon approximately 54 amino-acids downstream, and 13 codons upstream of the normal stop codon. This SFTPC mutation has not been reported previously. In our patient, this mutation was associated with early onset severe respiratory insufficiency and on autopsy was appeared as a nonspecific interstitial pneumonia.
Nogee et al. 3 published the first report of an association between mutation in SFTPC and a disease in a full-term female infant, who presented with respiratory distress at 6 weeks of age. Hamvas et al. 4 reported another infant with progressive and severe ILD associated with mutation in SFTPC gene. This infant was healthy until 3 months of age and subsequently developed growth failure and ILD resulting in lung transplantation by 14 months of age. Brasch et al. 7 reported a 13-month-old child with severe respiratory insufficiency associated with de novo missense mutation of SFTPC.
The mutations in the SFTPC gene have been associated with familial and sporadic ILD in children and adults. [2] [3] [4] [5] The clinical and histological expressions of these mutations have been variable with children exhibiting chronic pneumonitis of infancy or nonspecific ILD and adults exhibiting usual interstitial pneumonitis, desquamative interstitial pneumonitis or idiopathic pulmonary fibrosis.
The exact mechanisms of lung disease associated with SFTPC gene mutation are not completely known. The absence of mature SP-C in the large aggregate surfactant and juxtanuclear accumulation of pro-SP-C are consistent with a dominant-negative effect of presumably misfolded peptide that prevents normal pro-SP-C trafficking into the multivesicular and lamellar bodies. 8 It has been speculated that the aggregation of misfolded pro-SP-C may interfere with the unfolded protein response and result in toxic gain of function similar to that seen in mice that overexpress SP-C or in patients with Alzheimer's disease, alpha 1 antitrypsin deficiency and cystic fibrosis.
9,10 Surfactant dysfunction may be another factor that probably contributed to the infant's development of respiratory failure. Deficiency of SP-C could predispose a person to recurrent atelectasis, lung injury and inflammation. 2 Unlike surfactant protein B deficiency, the age at presentation of surfactant protein C mutation is variable and ranges from the neonatal period to adulthood. 11 The clinical presentation varies from mild tachypnea, respiratory distress and failure to thrive to progressive respiratory failure. The course of the infant in this case report was more severe than previous case reports with SFTPC mutations. The novel SFTPC gene mutation in this infant very likely led to a frameshift. Frameshift mutations often result in the unstable mRNA transcripts. This probably led to early disruption of SP-C metabolism and surfactant dysfunction with associated widespread lung injury and inflammation. 12 At present, there is no definite treatment for respiratory failure associated with mutation of SFTPC. Although, lung transplantation may be an option in progressive respiratory failure, 12 there are no clear guidelines for SFTPC mutation since the time of presentation and severity of illness are variable. Lung transplantation was successful in children with SFTPC gene mutation as noted in one case report. 4 Few cases of surfactant protein C deficiency treated with hydroxychloroquine have been reported. 1, 13 We report this case to highlight the high index of suspicion for SFTPC mutation in a neonate presenting with an unusual course of severe respiratory failure. This infant was found to have a novel SFTPC gene mutation.
